C20 Health Working Group

C20 Health Working Group

The G20* is a forum of the world’s major economics. It seeks to develop global policies to address today’s most pressing challenges. G20 members represent all inhabited continents, 85% of global economic output and 66% of the world’s population.** The majority of tuberculosis (TB) and drug-resistant TB cases are found in G20 countries and by 2050 drug-resistant TB could claim an additional 33 million lives in the G20, and cost US$ 10.5 trillion to G20 members collectively.

As such, the G20 is uniquely positioned and has a responsibility to address global health threats, including antimicrobial resistance (AMR) and TB. This includes funding new research and development (R&D) initiatives for preventive, diagnostic and treatment tools. The G20 should also ensure that the Global Fund is fully funded in its 2019 replenishment, in recognition of its crucial role in TB prevention, diagnosis, treatment, care and support.

In 2016, the G20 Leaders’ Communiqué described AMR as a “serious threat to public health, growth and global economic stability.”*** In 2017, global health was added to the G20 agenda, in recognition of its impact on finance and development, and AMR featured prominently. The 2017 Leaders’ Declaration gave several recommendations on AMR:

  • Committed to strengthen public awareness, infection prevention and control and improve the understanding of the issue of antimicrobials in the environment.
  • Promoted access to affordable and quality antimicrobials, vaccines and diagnostics.
  • Highlighted the importance of research and development (R&D), in particular for priority pathogens identified by WHO and tuberculosis (TB).
  • Called for, and invited all interested countries to join, a new international R&D Collaboration Hub on AMR.
  • Called for examination of practical market incentive options.
C20 opening by C20 Sherpa Maria Emilia Berazategui

C20 opening by C20 Sherpa Maria Emilia Berazategui

As TB civil society, we are pushing for the recognition of TB as the “cornerstone of the AMR threat” and for the G20 to prioritise it accordingly in any AMR initiatives. There are several ways we can engage:

  • Work with the official Civil Society 20 (C20) engagement group (see more information below) through their health working group. The C20 is one of the seven Engagement Groups**** of the G20. The C20 had its first face-to-face meeting in Buenos Aires in April and has recently agreed a position paper for presentation to the G20. The co-chair of the C20 health working group also has the opportunity to give interventions in the G20 health working group meetings ahead of the main summit.
  • Conduct national advocacy with G20 representatives, such as the Department for Health, Department for International Development, and Sherpa teams, to talk about the importance of G20 engagement and action on TB.
  • Work in coalition with civil society globally or regionally to coordinate national level advocacy on TB by streamlining key asks and messages.

The C20 became an Engagement Group of the G20 in 2013. It is a specific space for civil society organisations from around the world to contribute to the G20 in a structured manner. Within the C20, there are different work themes that can vary year to year, but it always seeks to reflect the perspective and experience of civil society in a diverse range of topics. Health is one of the work themes which is discussed in depth and a high-level policy paper is prepared for presentation to the G20. Any civil society organisations can participate in the C20 by signing up to the join, this includes access to the online forum, an invitation to the face to face meetings, and the opportunity to input into the final position paper of the group that is delivered to the G20 representatives. The C20 Summit will take place 6-7 August this year in Buenos Aires.

The Argentinian G20 Leaders’ Summit, 30 November – 1 December 2018, will happen against a backdrop of unprecedented political momentum for TB; following the November 2017 Global Ministerial Conference on TB in Russia and the September 2018 UN High-Level Meeting on TB. It is therefore a potential turning point in the fight against the epidemic and the G20 must collectively step up and show leadership.

For more information on engaging with any of the above groups or to access the final C20 Health Working Group position paper, please contact TB Policy Advocacy Officer at Results UK, Rachael Hore (rachael.hore@results.org.uk).

*19 countries (Argentina, Australia, Brazil, Canada, China, Germany, France, India, Indonesia, Italy, Japan, Mexico, Russia, Saudi Arabia, South Africa, South Korea, Turkey, the United Kingdom and the United States) and the European Union.
**G20, What is G20, G20 (Online). https://www.g20.org/en/g20/what-is-the-g20
***G20 Leaders’ Communique Hangzhou Summit [Online]. Available from: http://europa.eu/rapid/press-release_STATEMENT-16-2967_en.htm
****The other engagement groups for this year’s G20: Business 20, Labour 20, Science 20, Think 20, Women 20 and Youth 20.


This blog is the product of an activity that has received funding under an operating grant from the European Union’s Health Programme (2014-2020).

The content of this blog represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.